Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 clinical trial examining Xenon-129 MRI as a biomarker for diagnosis and treatment response in pulmonary arterial hypertension, curre…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Pulmonary Hypertension SOLAR [Phase 2]
Phase 2 clinical trial SOLAR investigating treatments for pulmonary hypertension associated with interstitial lung disease and COPD; the stu…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO) [NA]
This entry notes a clinical trial evaluating fetal endoscopic tracheal occlusion (FETO) for congenital diaphragmatic hernia with pulmonary h…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension [Phase 3]
Phase 3 open-label extension study of ralinepag in pulmonary arterial hypertension is ongoing, with enrollment by invitation to assess long-…
-
EMA approval · 2026-02-19EMA Authorised: Uptravi (selexipag) — Janssen Cilag International NV
The European Medicines Agency authorised Uptravi (selexipag) from Janssen Cilag International NV for pulmonary arterial hypertension.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 trial comparing monotherapy versus combination therapy for pediatric pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 clinical trial update for 2-HOBA in pulmonary arterial hypertension shows the study is currently not yet recruiting.
-
FDA approval · 2026-02-17FDA Approved: AMBRISENTAN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for ambrisentan (Actavis Pharma, Inc.), a drug used to treat pulmonary arterial hypertension. Th…
-
FDA approval · 2026-02-17FDA Approved: AMBRISENTAN — Supplemental Application (Sigmapharm Laboratories, LLC)
FDA approved a supplemental application for Ambrisentan submitted by Sigmapharm Laboratories, LLC.
-
FDA approval · 2026-02-17FDA Approved: BOSENTAN — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved Zydus Pharmaceuticals USA Inc.'s original application for Bosentan, indicating approval of a generic bosentan product.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
An upcoming clinical trial evaluating patient-reported outcomes and adherence after switching from inhaled iloprost to oral selexipag in pul…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: What is the Role of the Exposome in Pulmonary Hypertension
A clinical trial investigating how environmental exposures influence pulmonary arterial hypertension and chronic thromboembolic pulmonary hy…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) [Phase 3]
Open-label extension study PROSERA-EXT of seralutinib in adults with pulmonary arterial hypertension is ongoing in Phase 3, with the status …
-
EMA approval · 2026-02-05EMA Authorised: Yuvanci (macitentan;tadalafil) — Janssen-Cilag International NV
The EMA authorised Yuvanci, a fixed-dose combination of macitentan and tadalafil, for pulmonary arterial hypertension.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)
A clinical trial update about cognitive alterations in Pulmonary Arterial Hypertension. The study is currently active but not recruiting.
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH [NA]
A clinical trial investigating non-invasive measurement of cardiac output and stroke volume in pulmonary arterial hypertension and chronic t…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
A clinical trial update evaluating riociguat as part of triple therapy for pulmonary arterial hypertension in real-world practice; the study…
-
EMA approval · 2026-01-27EMA Authorised: Adcirca (previously Tadalafil Lilly) (tadalafil) — Eli Lilly Nederland B.V.
EU marketing authorisation granted for Adcirca (tadalafil) to treat pulmonary arterial hypertension; the marketing authorisation holder is E…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) [Phase 3]
Clinical trial update on Inhibikase Therapeutics' adaptive IKT-001 program for pulmonary arterial hypertension; the Phase 3 study is current…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension [Phase 1]
A Phase 1 trial of PNEUMOSTEM for improving respiratory outcomes in very premature infants with early pulmonary arterial hypertension; the s…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension [NA]
This clinical trial update describes a study evaluating exercise as an adjunct to standard medical therapy in patients newly diagnosed with …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating sotatercept in pulmonary arterial hypertension, using 68Ga-FAPI PET/CT imaging to assess remodeling of…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH [Phase 2]
Phase 2 clinical trial update on the efficacy and safety of riociguat for incipient pulmonary vascular disease as an early indicator for pul…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Dapagliflozin in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 clinical trial evaluating dapagliflozin for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension has co…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: PET Image in PAH Patients [EARLY_Phase 1]
An early-phase 1 study assessing PET imaging in patients with Pulmonary Arterial Hypertension is currently recruiting.